Ray McDermott

29.2k citations
211 papers · 20.8k · 25 hit papers · h-index 48

Impact in

  • Oncology top 0.2%
    • Cancer Immunotherapy and Biomarkers
    • Colorectal Cancer Treatments and Studies
    • PARP inhibition in cancer therapy
    • Prostate Cancer Treatment and Research
    • Renal cell carcinoma treatment
    • Gastric Cancer Management and Outcomes

Papers in

    • Prostate Cancer Treatment and Research 52
    • Renal cell carcinoma treatment 19
    • Sarcoma Diagnosis and Treatment 15
    • Lung Cancer Treatments and Mutations 13
    • Cancer Immunotherapy and Biomarkers 14
    • Pancreatic and Hepatic Oncology Research 12
    • Colorectal Cancer Treatments and Studies 11

Ray McDermott

202 papers receiving 20.4k citations

Ray McDermott's Hit Papers

Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial 2025 · 35 citations
350+1+3Years since publication200400600

Peers

Ray McDermott
Comparison fields: 5 of 119
  • Oncology 7.8k
  • Pulmonary and Respiratory Medicine 7.5k
  • Cancer Research 1k
  • Surgery 2.2k
  • Pathology and Forensic Medicine 885
Replace Toshihiko Doi with:
Toshihiko Doi Japan
Joon Oh Park South Korea
Jeeyun Lee South Korea
Hedy Lee Kindler United States
Won Ki Kang South Korea
Christophe Massard France
Sarina Anne Piha-Paul United States
Jae‐Lyun Lee South Korea
Ulka N. Vaishampayan United States
Antoîne Italiano France
Ray McDermott relative to Toshihiko Doi Japan Toshihiko Doi's profile →
Citations per field
00.5×1.5×1.9×
Toshihiko Doi · 1×
Citations per year

Countries citing papers authored by Ray McDermott

Since Specialization
Citations

This map shows the geographic impact of Ray McDermott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ray McDermott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ray McDermott more than expected).

Fields of papers citing papers by Ray McDermott

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ray McDermott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ray McDermott. The network helps show where Ray McDermott may publish in the future.

Co-authors

The 25 scholars most cited alongside Ray McDermott, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ray McDermott Line = papers co-authored together Ray McDermott links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 211 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Hit paper breakdown →
20192674
2
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Hit paper breakdown →
20172301
3
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
Hit paper breakdown →
20181691
4
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Hit paper breakdown →
20191188
5
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Hit paper breakdown →
20181060
6
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
Hit paper breakdown →
2020814
7
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
Hit paper breakdown →
2023728
8
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma
Hit paper breakdown →
2021698
9
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
Hit paper breakdown →
2020592
10
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
Hit paper breakdown →
2020561
11
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design
Hit paper breakdown →
2022560
12
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
Hit paper breakdown →
2021490
13 2017464
14
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
Hit paper breakdown →
2023446
15
Docetaxel-Resistance in Prostate Cancer: Evaluating Associated Phenotypic Changes and Potential for Resistance Transfer via Exosomes
Hit paper breakdown →
2012400
16
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
Hit paper breakdown →
2023326
17
Rucaparib or Physician’s Choice in Metastatic Prostate Cancer
Hit paper breakdown →
2023319
18 2020309
19
Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma
Hit paper breakdown →
2017305
20
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Hit paper breakdown →
2022212

About Ray McDermott

Ray McDermott is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Pathology and Forensic Medicine and Surgery, having authored 211 papers that have together received 20.8k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (52 papers), Renal cell carcinoma treatment (19 papers), Sarcoma Diagnosis and Treatment (15 papers), Cancer Genomics and Diagnostics (15 papers), Cancer Immunotherapy and Biomarkers (14 papers), Lung Cancer Treatments and Mutations (13 papers), Pancreatic and Hepatic Oncology Research (12 papers) and Colorectal Cancer Treatments and Studies (11 papers). The work is most often cited by research in Oncology (7.8k citations), Pulmonary and Respiratory Medicine (7.5k citations), Cancer Research (1k citations), Surgery (2.2k citations) and Pathology and Forensic Medicine (885 citations). Ray McDermott has collaborated with scholars based in Ireland, United States and France. Frequent co-authors include Thierry André, Scott Kopetz, Michael James Overman, Sara Lonardi, Rebecca Anne Moss, Zhu Alexander Cao, Heinz‐Josef Lenz, Jean-Marie Ledeine, Michael Andrew Morse and Jayesh Desai. Their work appears in journals such as Annals of Oncology, The Lancet Oncology, European Urology, Journal of Clinical Oncology and Cancers.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact